Xeris Biopharma (XERS)
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neur...
- Open
- 8.610
- High
- 8.810
- Low
- 8.535
- Prev. Close
- 8.600
- Volume
- 1.56M
- Turnover
- 13.59M
- Avg Price
- 8.698
- Bid/Ask Ratio
- --
- Amplitude
- 3.20%
- 52wk High
- 10.080
- Volume Ratio
- 1.01
- Turnover Ratio
- 0.89%
Xeris Biopharma Analyst Rating
View moreForecast & Rating
Aug 20, 2026Price forecast
$11.7134.65%
Forecast & RatingStrong buy
7analysts
- Strong buy71.43%
- Buy14.29%
- Hold14.29%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Aug 12 at 03:45 PM
Xeris Biopharma CFO Steven Pieper sells 5,000 shares worth $42,500
- Market Beat · Aug 7 at 03:04 PM
Xeris Biopharma Q2 Earnings Call Highlights
- benzinga_article · Aug 6 at 10:08 AM
Xeris Biopharma shares are trading lower after the company reported mixed Q2 financial results.
- Earnings Watch · Aug 6 at 06:17 AM
Xeris Biopharma | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 92.1 M
- PUBT · Aug 6 at 06:14 AM
Xeris Q2 FY26 net loss widens to $31.1 million; revenue rises 29% to $92.1 million
- MSN · Aug 5 at 12:33 PM
Xeris Pharmaceuticals Q2 2026 earnings preview
